Prometheus (UCLA) and Bayer HealthCare Enter into Services Agreement to Conduct Mutational Analysis (12/8/2010)

Prometheus Laboratories is a biotechnology company that develops diagnostic and therapeutic products. The company has been licensing technology from UCLA since 1996.

From the company’s press release:
Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, announced today the execution of an oncology-focused mutational analysis services agreement with Bayer Schering Pharma AG, Germany, a worldwide leading pharmaceutical company. The addition of this mutational analysis services agreement broadens Bayer’s oncology-focused molecular and pathway activation profiling collaboration with Prometheus to include comprehensive mutational analyses. The expanded information derived from this agreement has the potential to improve patient stratification in clinical studies and accelerate the development of novel oncology diagnostic and therapeutic products. read full press releaes

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s


%d bloggers like this: